HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MAT9001

An omega-3 free fatty acid formulation containing mainly eicosapentaenoic acid and docosapentaenoic acid.

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bobotas, George: 2 articles (11/2017 - 01/2017)
2.	Dicklin, Mary R: 2 articles (11/2017 - 01/2017)
3.	Maki, Kevin C: 2 articles (11/2017 - 01/2017)
4.	Dai Perrard, Xiao-Yuan: 1 article (11/2017)
5.	Lian, Zeqin: 1 article (11/2017)
6.	Wu, Huaizhu: 1 article (11/2017)
7.	Huebner, Margie: 1 article (01/2017)
8.	Keane, William F: 1 article (01/2017)

Related Diseases

1.	Atherosclerosis 11/01/2017 - "MAT9001 and EPA-EE each improved fasting and postprandial monocyte phenotypes, which could potentially help to protect against atherosclerosis."
2.	Hypertriglyceridemia 01/01/2017 - "MAT9001 produced significantly larger reductions than EPA-EE in several lipoprotein-related variables that would be expected to favorably alter cardiovascular disease risk in men and women with hypertriglyceridemia." 11/01/2017 - "Treatment with MAT9001 in individuals with hypertriglyceridemia reduced fasting nile red staining for lipids in classical and intermediate monocytes. " 11/01/2017 - "We examined effects of n-3 polyunsaturated fatty acid treatments (eicosapentaenoic acid [EPA] plus docosapentaenoic acid [MAT9001] vs EPA ethyl esters [EPA-EE]) on monocyte phenotypes in individuals with hypertriglyceridemia. "
3.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2017 - "MAT9001 produced significantly larger reductions than EPA-EE in several lipoprotein-related variables that would be expected to favorably alter cardiovascular disease risk in men and women with hypertriglyceridemia."

Related Drugs and Biologics

1.	Omega-3 Fatty Acids (Omega 3 Fatty Acids)
2.	Eicosapentaenoic Acid
3.	Lipoproteins (Lipoprotein)
4.	Lipids
5.	Esters
6.	nile red
7.	docosapentaenoic acid